{"id":"suvorexant-belsomra","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Somnolence / next-day drowsiness"},{"rate":"5-10","effect":"Headache"},{"rate":"3-5","effect":"Dizziness"},{"rate":"3-5","effect":"Abnormal dreams / nightmares"},{"rate":"1-3","effect":"Sleep paralysis"}]},"_chembl":{"chemblId":"CHEMBL1083659","moleculeType":"Small molecule","molecularWeight":"450.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Suvorexant is an orexin receptor antagonist that inhibits the activity of orexin neuropeptides, which are responsible for promoting wakefulness. By blocking orexin signaling, the drug reduces the drive to stay awake and facilitates sleep onset and maintenance. This represents a novel mechanism distinct from traditional sedating antihistamines or benzodiazepines.","oneSentence":"Suvorexant blocks orexin receptors in the brain to reduce wakefulness and promote sleep.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:20.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and sleep maintenance)"}]},"trialDetails":[{"nctId":"NCT05546554","phase":"PHASE2","title":"Trial of Suvorexant for Sleep in Children With Autism","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-08-09","conditions":"Autism, Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT05630781","phase":"NA","title":"Orexin s Role in the Neurobiology of Substance Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-02-15","conditions":"Nicotine Dependence","enrollment":140},{"nctId":"NCT06655883","phase":"PHASE3","title":"A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-09","conditions":"Insomnia","enrollment":300},{"nctId":"NCT06162663","phase":"PHASE4","title":"Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2024-09-20","conditions":"Breast Cancer, Insomnia","enrollment":5},{"nctId":"NCT05829655","phase":"EARLY_PHASE1","title":"Measuring Acute Drug Demand in Humans","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2023-08-08","conditions":"Opioid Use Disorder, Opioid Dependence","enrollment":75},{"nctId":"NCT06788522","phase":"PHASE4","title":"The Effects of Orexin Antagonism on Fear Extinction in PTSD","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-03-01","conditions":"Insomnia, PTSD","enrollment":40120},{"nctId":"NCT06484075","phase":"PHASE1, PHASE2","title":"Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2024-11-21","conditions":"Healthy Volunteers, Alcohol Use Disorder (AUD)","enrollment":180},{"nctId":"NCT06584942","phase":"PHASE4","title":"Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-10","conditions":"Cue-reactivity, Cannabis Use Disorder, Functional MRI","enrollment":20},{"nctId":"NCT05733286","phase":"PHASE2","title":"REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-06-28","conditions":"Delirium in Old Age","enrollment":142},{"nctId":"NCT06326684","phase":"EARLY_PHASE1","title":"Suvorexant and Alcohol","status":"RECRUITING","sponsor":"William Stoops","startDate":"2024-06-07","conditions":"Alcohol Use Disorder","enrollment":30},{"nctId":"NCT05546515","phase":"PHASE2","title":"Suvorexant for Opioid/Stimulant Co-use","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-12-01","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":20},{"nctId":"NCT04629547","phase":"PHASE2","title":"Sleep Trial to Prevent Alzheimer's Disease","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-05-25","conditions":"Sleep, Alzheimer Disease","enrollment":200},{"nctId":"NCT07214207","phase":"PHASE2","title":"Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2025-12-04","conditions":"Alcohol Use Disorder","enrollment":250},{"nctId":"NCT04287062","phase":"PHASE2","title":"Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-11-20","conditions":"Sleep Disturbance, Opioid-use Disorder","enrollment":138},{"nctId":"NCT05656534","phase":"EARLY_PHASE1","title":"Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2022-11-29","conditions":"Alcohol Use Disorder","enrollment":81},{"nctId":"NCT05908526","phase":"PHASE2","title":"Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2023-10-09","conditions":"Insomnia","enrollment":40},{"nctId":"NCT04092894","phase":"PHASE4","title":"Suvorexant and Sleep/Delirium in ICU Patients","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2020-02-28","conditions":"Insomnia, Sleep Fragmentation, Sleep Initiation and Maintenance Disorders","enrollment":100},{"nctId":"NCT04014387","phase":"PHASE4","title":"Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-06-02","conditions":"Treatment","enrollment":40},{"nctId":"NCT04234997","phase":"PHASE2","title":"Suvorexant to Reduce Symptoms of Nicotine Use","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-08-23","conditions":"Smoking Cessation","enrollment":14},{"nctId":"NCT06854224","phase":"PHASE2","title":"Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial","status":"RECRUITING","sponsor":"Marianne Goodman","startDate":"2025-09-01","conditions":"Suicide Risk, Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT05145764","phase":"PHASE2","title":"Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-03-30","conditions":"Suvorexant, Placebo, Opioid Use Disorder","enrollment":120},{"nctId":"NCT05593653","phase":"PHASE4","title":"Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-01-06","conditions":"Insomnia, Diabetes, Menopause","enrollment":61},{"nctId":"NCT06679062","phase":"PHASE2","title":"Suvorexant for Treatment of AUD and PTSD","status":"RECRUITING","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2025-07-16","conditions":"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia","enrollment":76},{"nctId":"NCT03642028","phase":"PHASE4","title":"Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-08-30","conditions":"Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic","enrollment":190},{"nctId":"NCT06834386","phase":"PHASE4","title":"Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2025-02-26","conditions":"Advanced Malignant Solid Neoplasm, Delirium, Hematopoietic and Lymphatic System Neoplasm","enrollment":""},{"nctId":"NCT05711862","phase":"PHASE2","title":"The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2023-03-09","conditions":"Methamphetamine Use Disorder","enrollment":7},{"nctId":"NCT05106153","phase":"PHASE1","title":"A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-17","conditions":"Healthy Non-dependent, Recreational Sedative Users, Abuse Potential","enrollment":127},{"nctId":"NCT04273776","phase":"EARLY_PHASE1","title":"A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walter Reed Army Institute of Research (WRAIR)","startDate":"2019-12-01","conditions":"Performance Enhancing Product Use","enrollment":90},{"nctId":"NCT03110315","phase":"PHASE4","title":"A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia","status":"COMPLETED","sponsor":"Theodore R. Brown, MD MPH","startDate":"2017-03-28","conditions":"Multiple Sclerosis, Fatigue, Insomnia","enrollment":36},{"nctId":"NCT04571944","phase":"PHASE3","title":"Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-22","conditions":"Delirium","enrollment":207},{"nctId":"NCT04262193","phase":"PHASE2","title":"Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder","status":"TERMINATED","sponsor":"Wayne State University","startDate":"2021-02-01","conditions":"Opioid-use Disorder, Sleep","enrollment":37},{"nctId":"NCT03818581","phase":"PHASE4","title":"Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-03-15","conditions":"Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder","enrollment":108},{"nctId":"NCT02729714","phase":"PHASE4","title":"A Pilot Study of Suvorexant for Insomnia in Parkinson Disease","status":"COMPLETED","sponsor":"Burdick, Daniel, M.D.","startDate":"2016-04","conditions":"Insomnia","enrollment":21},{"nctId":"NCT05823844","phase":"PHASE4","title":"Efficacy of Suvorexant on Post-operative Sleep Disturbance","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-01","conditions":"Postoperative Insomnia, Postoperative Delirium","enrollment":92},{"nctId":"NCT03412591","phase":"PHASE2, PHASE3","title":"The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2019-07-01","conditions":"Sleep Disturbance, Craving, Cortisol; Hypersecretion","enrollment":28},{"nctId":"NCT04706091","phase":"PHASE4","title":"Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-08-12","conditions":"Restless Legs Syndrome, Insomnia, Sleep Disorder","enrollment":46},{"nctId":"NCT03999099","phase":"PHASE1","title":"Targeting Orexin to Treat Nicotine Dependence","status":"UNKNOWN","sponsor":"Mclean Hospital","startDate":"2019-09-26","conditions":"Nicotine Dependence","enrollment":45},{"nctId":"NCT02849548","phase":"PHASE4","title":"Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Howard University","startDate":"2017-01-03","conditions":"Posttraumatic Stress Disorder","enrollment":27},{"nctId":"NCT04229095","phase":"PHASE2","title":"Medication Development in Alcoholism: Suvorexant Versus Placebo","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2021-11-17","conditions":"Alcohol Use Disorder (AUD)","enrollment":26},{"nctId":"NCT03897062","phase":"PHASE2","title":"Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence","status":"TERMINATED","sponsor":"The Florey Institute of Neuroscience and Mental Health","startDate":"2019-08-26","conditions":"Insomnia, Alcohol Use Disorder","enrollment":22},{"nctId":"NCT02704754","phase":"PHASE4","title":"Suvorexant and Trauma Related Insomnia","status":"COMPLETED","sponsor":"Howard University","startDate":"2016-05-01","conditions":"Insomnia, Posttraumatic Stress Disorder","enrollment":41},{"nctId":"NCT03937986","phase":"EARLY_PHASE1","title":"Suvorexant and Cocaine","status":"COMPLETED","sponsor":"William Stoops","startDate":"2019-07-11","conditions":"Cocaine Use Disorder","enrollment":8},{"nctId":"NCT02527564","phase":"PHASE4","title":"Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-09","conditions":"Insomnia, Bipolar Disorder","enrollment":61},{"nctId":"NCT03789214","phase":"PHASE2","title":"Medical Management of Sleep Disturbance During Opioid Tapering","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-07-01","conditions":"Opioid Dependence, Opioid Withdrawal, Sleep Disturbance","enrollment":90},{"nctId":"NCT03077620","phase":"NA","title":"Sleep Quality and Amyloid-Beta Kinetics","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-11","conditions":"Amyloid-beta","enrollment":48},{"nctId":"NCT03034018","phase":"PHASE4","title":"Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-05-25","conditions":"Insomnia","enrollment":60},{"nctId":"NCT03768713","phase":"PHASE4","title":"Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia","status":"UNKNOWN","sponsor":"Montana State University","startDate":"2019-04-18","conditions":"Chronic Insomnia","enrollment":34},{"nctId":"NCT02593682","phase":"PHASE4","title":"The Role of Orexin in Human Panic Disorder","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-05","conditions":"Panic Disorder","enrollment":3},{"nctId":"NCT02684136","phase":"PHASE4","title":"Suvorexant in Insomnia Co-morbid With Fibromyalgia","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2016-02-01","conditions":"Insomnia, Fibromyalgia","enrollment":10},{"nctId":"NCT03764683","phase":"PHASE4","title":"Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-02-26","conditions":"Bipolar Disorder, Insomnia","enrollment":""},{"nctId":"NCT02491788","phase":"PHASE4","title":"Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers","status":"COMPLETED","sponsor":"VA Palo Alto Health Care System","startDate":"2016-02-01","conditions":"Sleep Disorder, Shift-Work","enrollment":19},{"nctId":"NCT03158025","phase":"PHASE1","title":"A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-04-19","conditions":"Insomnia Disorders","enrollment":39},{"nctId":"NCT02785406","phase":"PHASE2","title":"Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-05","conditions":"Cocaine Use Disorder, Anxiety","enrollment":20},{"nctId":"NCT03312517","phase":"PHASE4","title":"Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2018-04-15","conditions":"Insomnia","enrollment":12},{"nctId":"NCT02750306","phase":"PHASE3","title":"Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-23","conditions":"Sleep Initiation and Maintenance Disorders, Alzheimer Disease","enrollment":285},{"nctId":"NCT03657355","phase":"PHASE1","title":"Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2018-09-07","conditions":"Healthy Recreational Drug Users","enrollment":63},{"nctId":"NCT01097629","phase":"PHASE3","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-03","conditions":"Primary Insomnia","enrollment":1020},{"nctId":"NCT02849184","phase":"PHASE4","title":"To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia","status":"COMPLETED","sponsor":"Jichi Medical University","startDate":"2017-01-17","conditions":"Hypertension, Insomnia","enrollment":82},{"nctId":"NCT02669030","phase":"PHASE4","title":"A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia","status":"UNKNOWN","sponsor":"Institute for Advanced Medical Research, Alpharetta, GA","startDate":"2017-03-01","conditions":"Depression, Major Depressive Disorder, MDD","enrollment":74},{"nctId":"NCT03755310","phase":"PHASE2","title":"Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant","status":"UNKNOWN","sponsor":"Diego García-Borreguero, MD, PhD","startDate":"2019-02","conditions":"Restless Legs Syndrome","enrollment":43},{"nctId":"NCT01059851","phase":"PHASE1","title":"Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-24","conditions":"Insomnia","enrollment":16},{"nctId":"NCT00792298","phase":"PHASE2","title":"Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11-05","conditions":"Primary Insomnia","enrollment":254},{"nctId":"NCT01021813","phase":"PHASE3","title":"A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-10","conditions":"Insomnia","enrollment":781},{"nctId":"NCT01097616","phase":"PHASE3","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-05","conditions":"Primary Insomnia","enrollment":1023},{"nctId":"NCT01293006","phase":"PHASE1","title":"Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-25","conditions":"Insomnia","enrollment":25},{"nctId":"NCT01300455","phase":"PHASE1","title":"Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-19","conditions":"Sleep Apnea","enrollment":26},{"nctId":"NCT01043926","phase":"PHASE1","title":"Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-22","conditions":"Insomnia, Hepatic Insufficiency","enrollment":16},{"nctId":"NCT01311882","phase":"PHASE1","title":"A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04","conditions":"Insomnia","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Suvorexant (Belsomra)","genericName":"Suvorexant (Belsomra)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Suvorexant blocks orexin receptors in the brain to reduce wakefulness and promote sleep. Used for Insomnia (sleep onset and sleep maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}